This page cites only published clinical and preclinical literature and distinguishes evidence quality at every claim. It does not substitute for medical advice.
Key Takeaways
- Most self-reported cognitive-use protocols start at 0.1 mg/day via nasal spray; Russian clinical neurological trials used 0.6 to 1.2 mg/day in patient populations.
- The difference between a 0.1% and 1% semax nasal solution is a 10-fold concentration gap that causes the most common dosing error.
- Semax's C-terminal Pro-Gly-Pro addition gives it meaningfully longer enzymatic stability than native ACTH(4-10), but its plasma half-life is still short; functional effects likely outlast plasma levels via BDNF/NGF induction.
- No published human RCT exists for semax in healthy adults at any dose; every dosing recommendation for nootropic use is extrapolated from patient trials or animal data.
- Third-party HPLC-verified COA with purity above 98% and endotoxin testing is the minimum quality bar for any injectable preparation.
How Many mg of Semax a Day: Direct Answer
For nootropic use in healthy adults, 0.1 to 0.3 mg/day intranasally is the most commonly cited range, based on downward extrapolation from published Russian clinical doses and community consensus. Russian neurological trials used 0.6 to 1.2 mg/day in stroke and cognitive-deficit patients. No human RCT in healthy adults exists to validate any specific dose.
Table of Contents
- Evidence Ledger: What We Actually Know About Semax Dosing
- Mechanism With Numbers: Why Dose Matters Biologically
- Semax Dosage Chart by Route and Goal
- What Most Pages Get Wrong: The Concentration Error That Causes 10x Overdosing
- The Chemistry Behind Dosing Rules
- Honest Head-to-Head: Semax vs. Its Real Alternatives
- Operational and Label Literacy: Reading a COA, Reconstitution Math, and Degradation Signals
- How Long Should a Semax Cycle Last?
- Side Effects by Dose Tier
- Frequently Asked Questions
- Sources
Evidence Ledger: What We Actually Know About Semax Dosing
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Semax 0.6 to 1.2 mg/day intranasally improves outcomes in ischemic stroke patients | Russian controlled clinical trials (patient populations, limited blinding detail in translated literature) | Positive vs. control | Moderate (replication in Western RCTs absent) |
| Semax increases BDNF and NGF expression in rodent brain tissue | Multiple animal studies (rat, mouse) | Upregulation confirmed | Moderate (animal; human translation unproven) |
| Semax has cognitive-enhancing effects in healthy humans at 0.1 to 0.3 mg/day | Community self-report only; no human RCT in healthy adults | Directionally positive (anecdotal) | Very Low |
| Pro-Gly-Pro C-terminal addition confers enzymatic resistance vs. native ACTH(4-10) | Peptide chemistry / in vitro degradation studies | Confirmed structural property | High |
| Intranasal bioavailability is lower than subcutaneous injection | General peptide pharmacokinetic principles; no published human head-to-head for semax specifically | Directionally established | Moderate (class evidence, not semax-specific human data) |
| Long-term daily semax use is safe in humans | No controlled long-term human safety data | Unknown | Very Low |
| Semax modulates dopamine and serotonin metabolism in animal CNS | Rodent neurochemistry studies | Modulation shown | Moderate (animal; mechanism direction, not dose confirmed in humans) |
Mechanism With Numbers: Why Dose Matters Biologically
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, derived from the ACTH(4-10) fragment with a C-terminal Pro-Gly-Pro extension. It does not bind the melanocortin MC2 (ACTH) receptor at meaningful affinity; its neuroactive profile is driven by separate mechanisms.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →BDNF and NGF induction: Animal studies (Dolotov et al., published in peer-reviewed Russian-language neuroscience journals and indexed on PubMed) show semax dose-dependently increases BDNF mRNA expression in rat brain, with effects observed at doses in the range of 50 to 250 mcg/kg intraperitoneally. Translating rodent IP doses to human intranasal doses is not straightforward; the comparison is provided only to illustrate the dose-response character, not to derive a human equivalent dose directly.
What the mechanism does NOT prove: Rodent BDNF upregulation does not establish that human cognitive function improves. BDNF elevation is correlational with neuroplasticity in humans, not causally sufficient at the timescales of a two-week self-experiment.
Monoamine effects: Animal neurochemistry research shows semax influences serotonin and dopamine turnover in regions including the striatum and frontal cortex. These findings are directionally consistent with reported stimulant-adjacent effects (focus, reduced fatigue) but do not define a therapeutic window in humans.
Half-life and dosing frequency: The native ACTH(4-10) fragment is rapidly cleaved by blood and tissue peptidases. The Pro-Gly-Pro addition to semax meaningfully slows this degradation. Preclinical pharmacokinetic descriptions report plasma disappearance on the order of minutes to low single-digit hours. Functional CNS effects in animal models outlast plasma presence, consistent with second-messenger and gene-expression changes (BDNF/NGF) rather than direct receptor occupancy duration. This supports once or twice daily dosing rather than every-few-hour micro-dosing.
Semax Dosage Chart by Route and Goal
| Context | Route | Dose Range | Frequency | Duration | Evidence Basis |
|---|---|---|---|---|---|
| Russian clinical trials (stroke / cognitive deficit) | Intranasal | 0.6 to 1.2 mg/day | Divided doses, 2 to 3x/day | 10 to 14 days | Controlled clinical trials (patient populations) |
| Community nootropic use, starting dose | Intranasal (0.1% solution) | 0.1 mg/day | 1x/day (morning) | 2 to 4 weeks then off | Extrapolation + self-report |
| Community nootropic use, moderate dose | Intranasal (0.1% solution) | 0.2 to 0.3 mg/day | 1 to 2x/day | 2 to 4 weeks then off | Extrapolation + self-report |
| Research injectable use (reported) | Subcutaneous | 0.1 to 0.3 mg/day | Once daily | Per protocol | Research literature; no published human RCT at these injectable doses for nootropic use |
What Most Pages Get Wrong: The Concentration Error That Causes 10x Overdosing
This is the most consequential practical error in semax dosing and nearly every dosage guide either misses it or buries it.
Semax nasal spray is commercially available (from Russian pharmaceutical sources, sold as Semax) in two main concentrations: 0.1% and 1%.
- 0.1% solution: 1 mg per mL. A standard nasal pump actuates approximately 0.1 mL per spray, delivering roughly 0.1 mg per spray.
- 1% solution: 10 mg per mL. The same pump actuation delivers roughly 1 mg per spray.
A user who has read "take 1 to 2 sprays" and applies that instruction to a 1% bottle instead of a 0.1% bottle takes 10 times the intended dose. This is not a theoretical risk; it is reported repeatedly in online nootropic communities as a cause of acute anxiety, palpitations, and sleep disruption.
When sourcing lyophilized powder for reconstitution, the same arithmetic applies: if you dissolve 5 mg into 5 mL of bacteriostatic water you get a 1 mg/mL (0.1%) solution. If you dissolve 5 mg into 0.5 mL you get 10 mg/mL (1%). Document your reconstitution math before every batch.
The Chemistry Behind Dosing Rules
Why avoid late-day dosing: Semax modulates dopaminergic and serotonergic tone and has been described in animal literature as increasing wakefulness-associated signaling. The practical consequence reported by users is sleep disruption from afternoon or evening doses. The mechanism is not fully characterized in humans but is consistent with monoamine activity in arousal circuits. This is why morning dosing is universally recommended: it is not an arbitrary rule.
Why semax degrades in solution over time: Peptides with free methionine at the N-terminus (Met-1 in semax's sequence) are susceptible to oxidation of the thioether sulfur to sulfoxide, which alters binding geometry and reduces bioactivity. This oxidation is accelerated by light, elevated temperature, and dissolved oxygen. A prepared solution stored at room temperature and exposed to light will degrade meaningfully over days to weeks. Lyophilized powder is far more stable. Once reconstituted, refrigerate, minimize freeze-thaw cycles, and use within the manufacturer's stated window (typically 2 to 4 weeks for refrigerated solution).
Why injectable and intranasal doses are not interchangeable: Intranasal peptide absorption relies on the olfactory epithelium and trigeminal pathway for CNS delivery, and on nasal mucosal absorption for systemic delivery. A significant fraction of an intranasal dose is cleared by mucociliary action before absorption. Subcutaneous injection delivers the full administered dose into circulation with predictable kinetics. Using an intranasal dose as your injectable dose without adjustment introduces risk of overdose, though published human data defining the exact bioavailability ratio for semax specifically do not exist.
Honest Head-to-Head: Semax vs. Its Real Alternatives
| Dimension | Semax (intranasal) | Selank (intranasal) | Modafinil (oral, approved) | Caffeine + L-Theanine (oral) |
|---|---|---|---|---|
| Human RCT evidence for cognitive effects | Patient populations only; none in healthy adults | Patient populations only; none in healthy adults | Yes; multiple RCTs in healthy adults and sleep-deprived subjects | Yes; multiple RCTs in healthy adults |
| Regulatory approval | Russia only (prescription) | Russia only (prescription) | FDA-approved (narcolepsy, shift-work, sleep apnea) | GRAS; no approval needed |
| Long-term safety data | None in healthy adults | None in healthy adults | Yes; post-marketing data | Extensive; centuries of use |
| Mechanism specificity | BDNF/NGF induction, monoamine modulation | Anxiolytic; GABAergic modulation | Dopamine/norepinephrine reuptake inhibition | Adenosine antagonism + GABA-A modulation |
| Abuse/dependence potential | Not established; low in animal models | Not established; low in animal models | Schedule IV (US); dependence reported | Mild caffeine dependence |
| Sourcing reliability | Unregulated research market; purity varies | Unregulated research market; purity varies | Compounded or Rx pharmacy; regulated | Commodity; widely tested |
| Where semax loses | Evidence quality, regulatory oversight, sourcing certainty, and long-term safety knowledge are all inferior to approved alternatives. | |||
Operational and Label Literacy: Reading a COA, Reconstitution Math, and Degradation Signals
What a legitimate semax COA must show:
- HPLC purity: at minimum 98%; peptide research-grade sources should state 99%+.
- Correct molecular identity: semax molecular formula is C37H51N9O10S, molecular weight approximately 813.9 g/mol. Any COA showing a different MW is a red flag.
- Sequence verification: mass spectrometry confirmation of the Met-Glu-His-Phe-Pro-Gly-Pro sequence.
- For injectable use: endotoxin (LAL) testing result in EU/kg or IU/mg, and sterility or bioburden testing.
- Independent lab: the testing lab should be named and independent from the vendor. An in-house COA without a third-party lab name is low-value evidence.
Reconstitution math example: You have a 5 mg lyophilized vial. You want a 0.1% (1 mg/mL) solution for use with a standard nasal pump delivering approximately 0.1 mL per actuation (approximately 0.1 mg per spray).
- Add 5 mL bacteriostatic water to the 5 mg vial.
- Each 0.1 mL actuation delivers 0.1 mg.
- Two sprays (one per nostril) = 0.2 mg per dose.
If you add only 0.5 mL, you produce a 10 mg/mL (1%) solution. The same two-spray actuation now delivers 2 mg. This is 10 times the intended dose.
Degradation signals to watch for:
- Yellow or amber discoloration in a solution that was previously clear: methionine oxidation or general peptide degradation.
- Cloudiness or visible particulate: precipitation, possible contamination.
- Off or sulfurous odor: methionine oxidation byproduct.
- Any of the above = discard. Do not use a degraded solution.
How Long Should a Semax Cycle Last?
Published Russian clinical protocols for neurological indications ran 10 to 14 days, administered in inpatient or closely supervised outpatient settings. The rationale was neurotrophin induction (BDNF/NGF), which peaks and then adapts with sustained stimulation in animal models, suggesting diminishing returns with prolonged continuous use.
Community practice converges on 2 to 4 week cycles followed by an equal off-period, though this is not evidence-derived. The off-period logic is receptor/response normalization, which is plausible given monoamine system adaptation but unproven at the specific intervals used.
There is no human data on what constitutes a safe maximum cumulative dose or number of cycles per year. Anyone doing extended self-experimentation is operating beyond the evidence base.
Side Effects by Dose Tier
| Dose Tier | Commonly Reported Effects | Evidence Source |
|---|---|---|
| 0.1 mg/day intranasal | Mild nasal irritation; occasional transient stimulation | Community self-report |
| 0.2 to 0.3 mg/day intranasal | Nasal irritation; sleep disruption if dosed late; mild anxiety in sensitive individuals | Community self-report |
| 0.6 to 1.2 mg/day intranasal (clinical range) | Tolerability described as acceptable in published patient-population trials; specific adverse event rates not consistently reported in translated literature | Clinical trial reports (patient populations) |
| Accidental 10x dose (concentration confusion) | Acute anxiety, palpitations, sleep disruption; reported in online nootropic communities | Self-report/case anecdote |
Frequently Asked Questions
How many mg of semax a day is typical?
Most self-reported protocols use 0.1 to 0.3 mg per day for cognitive use via nasal spray, split into 1 to 2 doses. Clinical Russian trials used higher doses (0.6 to 1.2 mg/day) in stroke and neurological patients, administered intranasally under supervision. There is no FDA-approved dosing guideline.
What is the difference between semax 0.1% and 1% nasal spray?
A 0.1% solution contains 1 mg/mL; each actuation of a standard nasal pump (approximately 0.1 mL) delivers roughly 0.1 mg per spray. A 1% solution contains 10 mg/mL, delivering roughly 1 mg per spray. Confusing the two concentrations leads to 10-fold dosing errors.
How much semax peptide should I take for cognitive enhancement?
No human RCT supports a specific dose for cognitive enhancement in healthy adults. Based on clinical neurological trial doses scaled downward and community reports, 0.1 to 0.3 mg/day is the most commonly cited starting range. Begin at 0.1 mg and assess tolerance before increasing.
What semax dosage did Russian clinical trials use?
Published Russian trials in stroke and cognitive deficit patients used intranasal doses ranging from 0.6 mg/day to 1.2 mg/day, sometimes administered over 10 to 14 day courses. These were patient populations under medical supervision, not healthy adults seeking nootropic effects.
Is semax nasal spray dosage different from injectable dosage?
Yes. Intranasal bioavailability via the olfactory/trigeminal route is estimated to be substantially lower than subcutaneous injection, though no head-to-head pharmacokinetic study in humans has been published. Injectable doses used in research contexts are typically lower in absolute mg than intranasal doses intended to reach equivalent CNS exposure.
How long should a semax cycle last?
Russian neurological protocols typically ran 10 to 14 day inpatient courses. Community self-experimentation commonly reports 2 to 4 week cycles followed by an equal off period. No controlled data exist on optimal cycle length for healthy adult use.
Can I take semax every day long-term?
Long-term daily safety in humans has not been studied in controlled trials. Animal studies show BDNF and NGF upregulation with repeated dosing, but also suggest receptor adaptation over time. The absence of long-term human safety data is a real gap, not a technicality.
What does a degraded or underdosed semax product look like?
Semax is a heptapeptide susceptible to oxidation and enzymatic cleavage. A degraded solution may appear yellow or cloudy rather than clear, and may have off-odor. Any precipitate in a solution that was previously clear is a discard signal. Underdosed product has no visible indicator, making third-party COA verification essential.
What is semax's half-life and how does that affect dosing frequency?
Semax is a synthetic ACTH(4-10) analogue with a proline-glycine-proline C-terminal addition that resists enzymatic degradation compared to native ACTH(4-10). Its plasma half-life is reported in preclinical literature as on the order of minutes to low hours. Functional CNS effects appear to outlast plasma levels, likely due to BDNF/NGF induction, supporting once or twice daily dosing rather than frequent micro-dosing.
How do I read a semax COA for dosing accuracy?
A legitimate COA should show HPLC purity above 98%, correct molecular weight confirmation (molecular formula C37H51N9O10S, MW approximately 813.9 g/mol), and microbial/endotoxin testing if injectable. Cross-check the batch number on the vial label against the COA. A COA from a vendor's own in-house lab without independent verification is low value.
Is semax legal to buy?
In the United States, semax is not FDA-approved as a drug and is not a scheduled controlled substance as of 2025. It is sold as a research compound. In Russia it is an approved prescription drug. Regulations vary by country; verify local rules before purchasing.
What are the most common side effects reported at typical doses?
At doses of 0.1 to 0.3 mg/day via nasal spray, community reports most commonly cite mild nasal irritation, transient anxiety or overstimulation, and sleep disruption when dosed late in the day. Serious adverse events have not been documented in published clinical literature at these dose levels, but systematic safety surveillance in healthy adults does not exist.
Sources
- Dolotov OV, Karpenko EA, Inozemtseva LS, et al. "Semax, an analogue of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus." Brain Research. Published in peer-reviewed literature indexed on PubMed; describes dose-dependent BDNF mRNA changes in rat brain following semax administration.
- Ashmarin IP, Nezavibatko VN, Levitskaya NG, et al. Studies on the neuroprotective and cognitive effects of semax in clinical and animal models; published in Russian-language and translated neuroscience journals. Primary source for 0.6 to 1.2 mg/day clinical dosing in stroke patients.
- Levitskaya NG, Sebentsova EA, Andreeva LA, et al. "Semax and its analogs: structure-activity relationships." Published in peptide pharmacology literature; addresses structural determinants of semax bioactivity including Pro-Gly-Pro terminal stability.
- Vignoli AL, Cantagallo A, et al. General peptide pharmacokinetics and intranasal delivery principles; used for class-level bioavailability discussion. Note: semax-specific human PK data are not available in peer-reviewed English-language literature as of this writing.
- Frey WH 2nd. "Intranasal delivery: bypassing the blood-brain barrier to deliver therapeutic agents to the brain and spinal cord." Drug Delivery Technology, 2002. Background on olfactory/trigeminal pathway for intranasal peptide CNS delivery.
- National Center for Biotechnology Information. PubChem Compound Summary for Semax (CID 107983). Molecular formula C37H51N9O10S, molecular weight 813.9 g/mol. Available at: pubchem.ncbi.nlm.nih.gov.
- U.S. Drug Enforcement Administration. Controlled Substances Schedules. Semax is not listed as a scheduled substance. Verified as of 2025 review.